Literature DB >> 11200774

Loss of heterozygosity in bilateral breast cancer.

J Kollias1, S Man, M Marafie, K Carpenter, S Pinder, I O Ellis, R W Blamey, G Cross, J D Brook.   

Abstract

Women who develop bilateral breast cancer at an early age are likely to harbour germline mutations in breast cancer susceptibility genes. The aim of this study was to test for concordant genetic changes in left and right breast cancer of young women (age < 50) with bilateral breast cancer that may suggest an inherited breast cancer predisposition. Microsatellite markers were used to test for loss of heterozygosity (LOH) in left and right tumours for 31 women with premenopausal bilateral breast cancer. Markers adjacent to or within candidate genes on 17p (p53), 17q (BRCA1), 13q (BRCA2), 11q (Ataxia Telangiectasia-ATM) and 3p (FHIT) were chosen. Mutational testing for BRCA1 and BRCA2 was performed for cases where blood was available. Concordant LOH in both left and right tumours was demonstrated for at least one of the markers tested in 16/31(54%) cases. Where allelic loss was demonstrated for both left and right breast cancer, the same allele was lost on each occasion. This may suggest a common mutational event. Four cases showed concordant loss of alleles in both left and right breast cancer at D17S791 (BRCA1). BRCA1 mutations were identified in two of these cases where blood was available. Four cases showed concordant LOH at D13S155 (BRCA2). Concordant LOH was further demonstrated in seven cases for D11S1778 (ATM) and four cases for D3S1300 (which maps to the FHIT gene), suggesting a possible role for these tumour suppressor genes in this subgroup of breast cancer patients. No concordant allelic loss was demonstrated for D17S786 suggesting that germline mutations in p53 are unlikely in such cases of bilateral breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200774     DOI: 10.1023/a:1026575619155

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Testing clonal relatedness of tumors using array comparative genomic hybridization: a statistical challenge.

Authors:  Irina Ostrovnaya; Colin B Begg
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  Contralateral breast cancers: Independent cancers or metastases?

Authors:  Colin B Begg; Irina Ostrovnaya; Felipe C Geyer; Anastasios D Papanastasiou; Charlotte K Y Ng; Rita A Sakr; Jonine L Bernstein; Kathleen A Burke; Tari A King; Salvatore Piscuoglio; Audrey Mauguen; Irene Orlow; Britta Weigelt; Venkatraman E Seshan; Monica Morrow; Jorge S Reis-Filho
Journal:  Int J Cancer       Date:  2017-09-28       Impact factor: 7.396

3.  Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.

Authors:  Irene Orlow; Diana V Tommasi; Bradley Bloom; Irina Ostrovnaya; Javier Cotignola; Urvi Mujumdar; Klaus J Busam; Achim A Jungbluth; Richard A Scolyer; John F Thompson; Bruce K Armstrong; Marianne Berwick; Nancy E Thomas; Colin B Begg
Journal:  J Invest Dermatol       Date:  2009-03-12       Impact factor: 8.551

4.  Molecular cytogenetic investigations of synchronous bilateral breast cancer.

Authors:  K Agelopoulos; N Tidow; E Korsching; R Voss; B Hinrichs; B Brandt; W Boecker; H Buerger
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

5.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

6.  Statistical tests for clonality.

Authors:  Colin B Begg; Kevin H Eng; Amanda J Hummer
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

7.  Analysis of gene alterations of mitochondrial DNA D-loop regions to determine breast cancer clonality.

Authors:  S Masuda; T Kadowaki; N Kumaki; X Tang; Y Tokuda; S Yoshimura; S Takekoshi; R Y Osamura
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

8.  Cancer and the FRA3B/FHIT fragile locus: it's a HIT.

Authors:  K Huebner; C M Croce
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.